A phase Ill trial of docetaxel versus docetaxel and radium-223 (Ra-223) in patients with metastatic castration-resistant prostate cancer (mCRPC): DORA Meeting Abstract
| Authors: | Morris, M. J.; De Wit, R.; Vogelzang, N. J.; Tagawa, S. T.; Higano, C. S. |
| Abstract Title: | A phase Ill trial of docetaxel versus docetaxel and radium-223 (Ra-223) in patients with metastatic castration-resistant prostate cancer (mCRPC): DORA |
| Meeting Title: | 2019 Genitourinary Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 37 |
| Issue: | 7 Suppl. |
| Meeting Dates: | 2019 Feb 14-16 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2019-03-01 |
| Language: | English |
| ACCESSION: | WOS:000489108800024 |
| DOI: | 10.1200/JCO.2019.37.7_suppl.TPS348 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: TPS348 -- Source: Wos |
